Trial Profile

Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (PL101-ALS501)

Status: Active, no longer recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pridopidine (Primary) ; Pridopidine (Primary)
Indications Amyotrophic lateral sclerosis
Focus Expanded access; Therapeutic Use
Acronyms EAP 2; Pridopidine EAP 2
Sponsors Prilenia Therapeutics

Most Recent Events

18 May 2025 Status changed from recruiting to active, no longer recruiting.
27 Apr 2025 Huntington's disease has been removed from the study protocol.
19 Jan 2024 According to a Prilenia Therapeutics media release, enrollment phase is anticipated to start in the Spring of 2024. The expanded access programme will be conducted at up to 45 enrolling centers across the U.S.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com